Orthobunyavirus in human encephalitis and its diagnostic and therapeutic applications

A kit for the detection of Moissiacense virus nucleic acid, comprising:

• at least one oligonucleotide probe or primer selected from the group consisting of:
• the sequences of 5 to 100 nucleotides, preferably 15 to 60 nucleotides having 80% to 100% identity with any of SEQ ID NO:
• 1, 3, 5, and 7 to 9, which are specific for Moissiacense virus;
• and their complement, and
• reagents for the amplification of a target sequence and/or the detection of an amplification product.

A kit for the detection of Moissiacense virus antigen or antibody, comprising:

• a) at least an antigen from Moissiacense virus or an antibody thereto, wherein the antigen comprises an amino acid sequence selected from the group consisting of:
• a sequence having 90 to 100% with SEQ ID NO:
• 2 or a fragment of at least 10 amino acids of said sequence which is bound by antibodies against Moissiacense virus;
• a sequence having 90 to 100% identity with SEQ ID NO:
• 58 or 60 or a fragment of at least 10 amino acids of said sequence which is bound by antibodies against Moissiacense virus;
• an extracellular fragment of the sequence SEQ ID NO:
• 58 which is of at least 10 amino acids of said sequence and which is bound by antibodies against Moissiacense virus;
• and
• a fragment having the sequence of any of SEQ ID NO:
• 61 to 64, which is bound by antibodies against Moissiacense virus, and
• b) reagents for the amplification of a target sequence and/or the detection of an amplification product.

An immunogenic or vaccine pharmaceutical composition comprising, as active substance an antigen from Moissiacense virus comprising an amino acid sequence selected from the group consisting of:

• a sequence having 90 to 100% with SEQ ID NO:
• 2 or a fragment of at least 10 amino acids of said sequence which is bound by antibodies against Moissiacense virus;
• a sequence having 90 to 100% identity with SEQ ID NO:
• 58 or 60 or a fragment of at least 10 amino acids of said sequence which is bound by antibodies against Moissiacense virus;
• an extracellular fragment of the sequence SEQ ID NO:
• 58 which is of at least 10 amino acids of said sequence and which is bound by antibodies against Moissiacense virus;
• and
• a fragment consisting of the sequence of any of SEQ ID NO:
• 61 to 64, which is bound by antibodies against Moissiacense virus,
• wherein the composition further comprises at least one pharmaceutically acceptable adjuvant.